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OPD is a heterogeneous disease characterized by 
airﬂ  ow obstruction that is not fully reversible and 
is associated with a progressive decline in lung func-
tion.  1    Airway  inﬂ  ammation in COPD is usually neu-
trophilic,  2,3     but eosinophilic airway inﬂ  ammation has 
been found at stable state    4,5     and during exacerbations.    6,7   
Pathologic processes in COPD include destruction of 
lung parenchyma and changes within the large and 
small airways.    8     This evident disease heterogeneity 
cannot be deﬁ  ned by the FEV  1   alone, and alternative 
methods need to be sought to develop mechanistic, 
prognostic, and therapeutic applications in the man-
agement of COPD.    9     CT imaging has emerged as a 
noninvasive tool in the “phenotyping” of COPD, with 
measures investigating changes in the airway wall and 
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    Results:       The presence of emphysema (EM), bronchiectasis (BE), and bronchial wall thickening 
(BWT) was found in 67%, 27%, and 27% of subjects, respectively. The presence of EM was associ-
ated with lower lung function (mean difference % FEV  1  ,   2  20%; 95% CI,   2  28 to   2  11;   P    ,   .001). 
There was no difference in airway inﬂ  ammation, exacerbation frequency, or bacterial load in 
patients with EM alone or with BE and/or BWT      EM. The diffusing capacity of the lung for car-
bon monoxide/alveolar volume ratio     was the most sensitive and speciﬁ  c parameter in identifying 
EM (area under the receiver operator characteristic curve, 0.87; 95% CI, 0.79-0.96). Physiologic 
cluster analysis identiﬁ  ed three clusters, two of which were EM predominant and the third char-
acterized by a heterogeneous combination of EM and BE. 
    Conclusions:       The application of CT imaging can be useful as a tool in the multidimensional 
approach to phenotyping patients with COPD.       CHEST 2011; 140(3):634–642     
    Abbreviations:  BE  5   bronchiectasis;   BWT  5   bronchial wall thickening; D  lco   5   diffusing capacity of the lung for carbon 
monoxide  ;  EM  5   emphysema  ;  RV  5   residual volume; V  a   5   alveolar volume 
  The Role of CT Scanning in 
Multidimensional Phenotyping of COPD 
  Mona    Bafadhel ,   MBChB ;   Imran    Umar ,   BSc ;   Sumit    Gupta ,   MBBS ;   J.  Vimal    Raj ,   MBBS ; 
 Dhiraj  D.    Vara ,   BSc ;   James  J.    Entwisle ,   MBBS ;   Ian  D.    Pavord ,   DM ; 
 Christopher  E.    Brightling ,   PhD ,  FCCP;  and   Salman    Siddiqui ,   PhD    
  Manuscript received November 22, 2010    ; revision accepted 
February 19, 2011. 
  Afﬁ  liations:   From  the Department of Infection, Immunity and 
Inﬂ  ammation (Drs Bafadhel, Pavord, Brightling, and Siddiqui and 
Mr Umar), University of Leicester; the Department of Radiology 
(Drs Gupta, Raj, and Entwisle); and the Department of Respira-
tory Physiology (Mr Vara), University Hospitals of Leicester NHS 
Trust, Leicester, England    . 
  Drs Brightling and Siddiqui were joint senior authors of this article. 
  Funding/Support:   Dr Bafadhel is funded by a grant from the 
Medical Research Council, and Dr Brightling is funded by a 
Wellcome Senior Clinical Fellowship [03/91/68] that requires 
Open Access placement. The     research was performed in labo-
ratories partly funded by the European Regional Development 
Fund [ERDF 05567]. 
  Correspondence to:   Salman Siddiqui, PhD, Institute for Lung 
Health, University of Leicester, Department of Infection, Immunity 
and Inﬂ  ammation, Clinical Sciences Wing, Glenﬁ  eld Hospital, 
Groby Road, Leicester, LE3 9QP, England; e-mail: salman95@
yahoo.com   
  © 2011 American College of Chest Physicians.   This is an 
Open Access article distributed under the terms of the Creative 
Commons Attribution-Noncommercial License (  http://creative
commons.org/licenses/by-nc/3.0/  ), which permits unrestricted 
use, distribution, and reproduction in any medium, provided the 
original work is properly cited. Information for commercial entities 
is available online (  http://www.chestpubs.org/site/misc/reprints.xhtml  ). 
  DOI: 10.1378/chest.10-3007 www.chestpubs.org CHEST / 140 / 3 / SEPTEMBER, 2011    635 
overall impairment, with zero indicating best possible health sta-
tus and 100 indicating worst possible health status; the Chronic 
Respiratory Disease Interviewer-Administered Questionnaire 
(McMaster University; Hamilton, Ontario, Canada),    28    which  mea-
sures disease-speciﬁ  c quality of life with scores ranging from 1 to 7, 
with a higher score indicating a better quality of life for the 
domains of emotion, mastery, dyspnea, and fatigue; and the 
visual analog scale (VAS) for the domains of cough, breathless-
ness, sputum production, and sputum purulence, which consists of 
a 100-mm line for each measured domain, with “no symptoms” at one 
end and “the worst symptoms ever” at the other.    29    Body  composi-
tion was calculated using BMI.    30     Spontaneous or induced sputum 
was collected and analyzed for bacteria,    31    including  colony-forming 
units.  32     Quantitative real-time polymerase chain reaction was used 
to estimate the total bacterial load based on the abundance of 
16S ribosomal subunit encoding genes. In brief, bacterial DNA 
was extracted from homogenized sputum according to the 
manufacturer’s instructions, using the QIAmp DNA Mini Kit 
assay (QIAGEN, Ltd; Hilden, Germany). Quantiﬁ  cation of the 
total bacterial load was performed using the SYBR green assay 
(PE Applied Biosystems; Warrington, England    ). Sputum samples 
were then processed to produce cytospins for cell differential.  33,34   
Venous blood was collected for assessment of peripheral blood 
differential cell counts and serum C-reactive protein. 
 CT  Imaging 
  CT imaging was performed using a Sensation 16-slice scanner 
(Siemens Healthcare; Knoxville, Tennessee). Sequential scanning 
was performed at maximal inspiration from the apex to the dia-
phragm at 10-mm increments, with 1-mm collimation, while patients 
were in the supine position    . Image reconstruction was per-
formed by using a high-spatial-frequency algorithm through a 
512  3   512 matrix with a small ﬁ  eld of view. Scanning time ranged 
from 30 to 45 s with a 120-kV peak and an effective tube current 
of 140 mA. Images were reported at a window width and level of 
1,600 and   2 500  Hounsﬁ  eld units, respectively. CT scan qualita-
tive radiologic reporting for EM, BE, and BWT was performed in 
accordance with published guidelines.    35     BE was present when 
one or more of the following criteria were fulﬁ  lled: (1) an internal 
diameter of the bronchus greater than that of the adjacent pul-
monary artery, (2) a lack of tapering of the bronchial lumen toward 
the periphery, or (3) visualization of the bronchus within 10 mm 
of the pleural space. EM was present when focal areas of low 
attenuation without visible walls were detected, and included the 
presence of centrilobular, panlobular, and paraseptal EM. BWT 
was assessed subjectively as described previously.    36    Previous  stud-
ies at our institution have shown that the qualitative description 
method of EM, BWT, and BE has good interobserver agreement 
and image reconstruction; scanning and reporting was optimized 
for analysis of BWT, EM, and BE as previously described.    36   
 Statistical  Analysis 
  Statistical analysis was performed using PRISM, version 4 
(GraphPad Software; San Diego, California) and SPSS, version 16 
(SPSS Inc; Chicago, Illinois). Parametric and nonparametric data 
are presented as mean (SEM) and median (interquartile range) 
unless stated otherwise. Log-transformed data are presented as 
geometric mean (95% CI). For comparison of unpaired or paired, 
parametric or nonparametric groups, the Student   t   test, paired 
  t   test, Mann-Whitney test, and Wilcoxon matched pairs test 
were used, respectively    . For comparison of three groups or more 
for parametric and nonparametric variables, the one-way analysis 
of variance or Kruskal-Wallis test was used and the   x  2   test was 
used for proportions. Logistic regression analysis was used    37    to 
assess the relationship of the dependant variables of (1) presence 
lumen and within the lung parenchyma,    10-12    as  well 
as assessments of the degree of emphysema (EM) 
and burden of small airways disease    . CT imaging 
quantitative assessments have shown, inter alia, asso-
ciations with parameters of airway physiology,    13-15   
important COPD outcome measures,    15-18    and  sys-
temic inﬂ  ammatory mediators.    19   
  However, the role of CT imaging in deﬁ  ning COPD 
phenotypes above and beyond conventional charac-
terization with full lung function (spirometry, static 
lung volumes, and gas transfer) remains to be fully 
determined. Furthermore, the validity of CT imag-
ing as a biomarker of airways disease has yet to be 
established.  20,21   
  We hypothesized that CT imaging provides addi-
tional value to clinical and physiologic parameters 
in the multidimensional phenotyping of COPD. We 
tested our hypothesis by evaluating whether pheno-
typing of COPD using factor and cluster analysis 
with lung function parameters (physiologic clustering) 
would generate the radiologic COPD disease groups 
seen in clinical practice (EM, bronchial wall thick-
ening [BWT], and bronchiectasis [BE]). 
  Materials and Methods 
 Patients 
  Patients with a physician diagnosis of COPD as per GOLD 
(Global Initiative for Chronic Obstructive Lung Disease) criteria    1   
were recruited consecutively from general respiratory clinics and 
through local advertising to enter the longitudinal Biomarkers in 
COPD Exacerbation study. Patients with a diagnosis of asthma, 
current active pulmonary TB, or any other clinically relevant 
lung disease were excluded. All patients had obstructive spirom-
etry with a postbronchodilator FEV  1  /FVC ratio of   ,  0.7,  whereas 
severity was classiﬁ  ed according to the GOLD criteria.    1    Patients 
with COPD who demonstrated bronchodilator reversibility were 
not excluded. All patients gave written informed consent, and 
the study was approved by the Leicestershire, Northamptonshire, 
and Rutland ethics committee     (REC 07/H0406/157). 
 Study  Design 
 Seventy-ﬁ  ve patients enrolled in the Biomarkers in COPD 
Exacerbation study, who had previously undergone a CT scan as 
part of their clinical management, were studied. The median 
(interquartile range) interval time between patient characteriza-
tion and CT scanning was 15 (25) months. 
 Measurements 
  All patients had complete demographic data recorded, includ-
ing age, duration of symptoms, and full smoking and medical 
history. Full lung function, including reversibility testing with 
400   m  g inhaled albuterol, was also performed according to the 
American Thoracic Society/European Respiratory Society con-
sensus guidelines.    22-26     Health status and symptom scores were mea-
sured using the St. George Respiratory Questionnaire (University 
of London; London, England),    27     a two-part questionnaire measur-
ing recollection of symptoms and assessment of current activity 
and impact, in which scores are expressed as a percentage of 636  Original Research
identify the presence of EM was 0.87 (95% CI, 
0.79-0.96) (  Fig 2    ). All of the conventional measures 
of lung function (FEV  1 ,  D lco /V a  , RV, and FEV  1 /FVC) 
were reliable in distinguishing between EM only 
and EM plus BE and/or BWT (EM    1  BE/BWT), 
with receiver operator characteristic curves of   ,  0.6 
( Fig  3  ). 
  In contrast to this, patients with radiologic EM in 
the presence or absence of BE and/or BWT did not 
have any signiﬁ  cant difference in markers of proximal 
airway inﬂ  ammation (sputum total cell count and cel-
lular differential count) or bacterial load (measured 
of EM, (2) presence of BE, and (3) presence of BWT with explan-
atory (independent) variables, using the block entry method. Vari-
ables entered into the logistic regression model, chosen for clinical 
relevance, were the following continuous variables: FEV  1   % pre-
dicted, diffusing capacity of the lung for carbon monoxide (D lco )/
alveolar volume (V  a  ), residual volume (RV) % predicted, total 
sputum neutrophil count, and percentage sputum eosinophils (both 
log transformed). Model inspection showed no multicollinearity, 
goodness of ﬁ  t was performed using the Hosmer-Lemeshow 
  x  2   test, and the NagelKerke   R  2   was used to estimate the variance 
explained by the model. The Wald test was used to assess the 
signiﬁ  cance of the individual dependant variables to the model. 
Unsupervised multivariate modeling using principal component 
factor reduction analysis (orthogonal varimax rotation method) 
was used to explore airway physiologic pattern expression in the 
patients. Hierarchic cluster analysis was then applied from the 
identiﬁ  ed factors to determine physiologic clusters of COPD. 
Clinical characteristics for the physiologic clusters were tabulated. 
One-way analysis of variance, Kruskal Wallis, and the   x  2   test were 
used to compare parametric, nonparametric, and proportions of 
clinical characteristics between physiologic cluster groups. A   P   value 
of   ,   .05 was deemed to be statistically signiﬁ  cant. 
 Results 
  CT data were available in 75 patients (58 men, 
17 women). The most common clinical indication for 
CT scanning was investigation or exclusion of malig-
nancy (40%), followed by assessment for radiographic 
evidence of BE (30%) and suitability for lung volume 
reduction surgery (20%). The clinical characteristics 
of patients are shown in   Table 1    .  
  EM, BE, and BWT Are Common Radiologic 
Observations in COPD, With Signiﬁ  cant Overlap 
  The CT scan description of EM, BE, and BWT 
was present in 67%, 27%, and 27%, respectively. 
The number of patients with EM, BE, and BWT, and 
the associated overlap, are shown in   Figure 1    . No evi-
dence of EM, BE, or BWT on CT scanning was 
found in 13 patients in the COPD cohort. Subjects 
with CT scan evidence of disease had worse lung 
function, but there was no difference in demo-
graphic distribution, health status, or symptom scores 
( Table  2  ). 
  Conventional Lung Function Reliably Identiﬁ  es 
Patients With Radiologic EM and COPD 
  CT scan evidence of EM compared with no evi-
dence of EM was associated with lower lung func-
tion (39 vs 61; mean difference,   2  22%; 95% CI,   2 30 
to   2 13;   P   ,    .001), impaired D  lco   (3.8 vs 5.6; mean 
difference,   2  1.8; 95% CI,   2  2.7 to   2 0.9;   P   ,  .001),  and 
increased airway obstruction (FEV  1  /FVC) (0.43 vs 0.57; 
mean difference,   2  0.14; 95% CI,   2  0.20 to   2 0.08; 
  P   ,   .001). The receiver operator characteristic curve 
(area under the curve) for the D  lco /V a   to correctly 
  Table 1—  Clinical Characteristics of Patients With 
COPD With Corresponding CT Scan   
Characteristic    
Patients With COPD With 
CT scan Data (n   5   75)
Male, No. (%)  58 (77)
Age, y, mean (range) 67 (43-88)
Current smoker, No. (%) 24 (32)
Ex-smoker, No. (%) 50 (67)
Pack-y smoked, mean (range) 48 (10-153)
Exacerbation history in previous y 4.3 (0.3)
BMI, kg/m  2 26.1  (0.6)
ICS usage, No. (%) 68 (91)
ICS dosage,   m  g 1424 (92)
FEV  1 , a   L 1.22 (0.06)
FEV  1   % predicted  a   46  (2)
Reversibility, % 3 (1)
FEV  1 /FVC, a   % 47 (2)
SGRQ total, units 55.2 (2.0)
CRQ total, units 4.00 (0.13)
VAS total, mm 147 (9)
Sputum total cell count   3  10 6   cells/g, 
  geometric mean (95% CI)
3.8 (2.8-5.3)
Sputum neutrophils, % 69 (3)
Sputum eosinophils, %, geometric 
  mean (95% CI)
1.3 (0.9-1.9)
Data are presented as mean (SEM) unless otherwise indicated. 
CRQ  5    Chronic Respiratory Disease Interviewer-Administered Ques-
tionnaire; ICS   5   inhaled corticosteroid; SGRQ   5   St. George Respiratory 
Questionnaire; VAS   5   visual analog scale.
  a Postbronchodilator.
  Figure   1. Nonproportional Venn diagram representing patients 
with EM, BE, and BWT on CT scanning. BE   5   bronchiectasis; 
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  Conventional Lung Function Fails to Identify 
Patients With BE and BWT in COPD 
 Having  conﬁ  rmed that static lung volumes and 
transfer factor were predictive of radiologic EM, we 
sought to identify whether these markers could inde-
pendently group patients with EM-predominant 
disease (EM  1  ) or disease without EM     (EM  2  ) in the 
presence or absence of BWT/BE, using unsupervised 
statistical techniques. Principal component analysis 
using airway physiologic parameters in all patients with 
full physiologic testing and CT scan (n    5   64)  identi-
ﬁ  ed three factors with eigen values   .  1  ( Table  5  ), 
highlighting the following dominant physiologic com-
ponents: (1) RV, (2) D  lco /V a  , and (3) lung capacity. 
Hierarchic cluster analysis determined three cluster 
groups. Two were EM predominant, discrete only 
in their degree of air trapping and gas transfer. The 
third cluster was characterized by a heterogeneous 
combination of EM and BE, with preservation of gas 
transfer and lung volumes (  Table 6    ). 
  Repeatability of Airway Physiologic Phenotypes 
  Forty-seven patients had spirometry performed 
12 months after the initial characterization visit. In 
these patients, the repeatability of the measures of 
FEV  1   and FVC was good, with intraclass coefﬁ  cients of 
0.91 and 0.82, respectively (  P   ,   .001). There was no dif-
ference in the mean change in lung function for each 
of the physiologic clusters identiﬁ  ed after 12 months 
(cluster 1 [EM-predominant, moderate lung func-
tion], 0.03; 95% CI,   2  0.11 to 0.17; cluster 2 [heteroge-
neous, lung function preserved],   2  0.13; 95% CI,   2 0.23 
to   2  0.03; and cluster 3 [EM-predominant, severe lung 
function], 0.00; 95% CI,   2  0.12 to 0.12;   P   5   .17). 
by colony-forming units and abundance of 16S ribo-
somal subunit encoding genes) (  Table 3    ). 
  Static Lung Volume and Transfer Factor 
Are Independent Predictors of EM in 
COPD, But Not of BE or BWT 
 The  D lco /V a   and RV were conﬁ  rmed by logistic 
regression analysis to be independent predictors of 
EM on CT scanning in patients with COPD. In con-
trast, the variables entered into the model were not 
independent predictors of BE or BWT (  Table 4    ). 
  Table 2—  Clinical Comparisons in Patients With Demonstrable Absence or Presence of CT Scan Evidence 
of EM, BE, or BWT       
Characteristic Absence of EM/BE/BWT (n   5   13) Presence of EM/BE/BWT (n   5   62)  P   Value
Male, No. (%) 8 (62) 50 (81) 0.63
Age, y, mean (range) 68 (49-88) 67 (43-85) .90
Pack-y smoked mean (range) 35 (10-68) 50 (10-153) .10
Exacerbation history in previous y 3.7 (0.9) 4.4 (0.3) .43
ICS dosage,   m  g 831 (213) 1548 (95)   ,  .001
FEV  1   % predicted  a  62 (5) 43 (2)   ,  .001
FEV  1 /FVC, a   % 59 (3) 45 (2)   ,  .001
SGRQ total, units 50.3 (5.9) 56.4 (2.0) .23
CRQ total, units 4.21 (0.35) 3.95 (0.14) .45
VAS total, mm 149 (16) 146 (10) .92
Sputum total cell count   3  10 6   cells/g, 
  geometric mean (95% CI)
3.5 (1.9 -6.6) 3.9 (2.7-5.6) .82
Sputum neutrophils, % 66 (5) 70 (3) .64
Sputum eosinophils, %, 
  geometric mean (95% CI)
1.2 (0.5-2.8) 1.3 (0.9-2.0) .83
Data are presented as mean (SEM) unless otherwise indicated. BE   5   bronchiectasis; BWT  5   bronchial wall thickening; EM   5   emphysema. 
See Table 1 legend for expansion of other abbreviations.
  a Postbronchodilator.
  Figure   2. Receiver operator characteristic curve (sensitivity and 
1-speciﬁ  city) of diffusing capacity of the lung for carbon monox-
ide corrected for alveolar volume for identifying emphysema.     638  Original Research
with COPD, whereas the presence of BWT alone is 
sparse. Current guidelines use bedside spirometry and 
FEV  1   to diagnose and guide the severity of COPD.    1   
Although this tool can be widely applied, it has less 
accuracy when used to measure small airways dys-
function (airways with internal diameter   ,  2  mm).  9   
Using CT imaging, we have shown that, in patients 
with COPD, there are variation and overlap in the 
associated pathologic ﬁ  ndings. Thus, the use of FEV  1  
alone to diagnose and guide management in COPD 
highlights that spirometry cannot deﬁ  ne these patho-
logic processes with clarity. Our ﬁ  nding of BE in those 
with spirometric classiﬁ  cation of COPD is compara-
ble to those observed previously    38    and  highlights 
the heterogeneity that exists, which can, in turn, be 
partly delineated by radiologic characterization.    38-40   
  In patients with EM on CT scan, we found wors-
ened lung function, airﬂ  ow obstruction, and larger 
increases in residual lung volume, compared with 
patients with radiologic evidence of BE or BWT, 
although the clinical parameters of airway inﬂ  am-
mation, health status, and microbiologic qualitative 
or quantitative inﬂ  ammation are indistinguishable 
between these radiologic phenotypes. This is in keep-
ing with previous physiologic observations    15    and 
 Discussion 
  In this study, we have shown that there is overlap 
in radiologic evidence of EM, BE, and BWT in patients 
  Figure   3. Receiver operator characteristic curves for distin-
guishing the presence of emphysema alone vs emphysema plus 
bronchiectasis and/or bronchial wall thickening. D  lco /V a   5    
diffusing capacity of the lung for carbon monoxide/alveolar volume; 
RV  5   residual  volume.   
  Table 3—  Airway Inﬂ  ammometry, Physiology, and Health Status in Patients With EM Alone, 
BE and/or BWT Without EM, and EM With BWT and/or BE   
Characteristic EM (n   5   29) BE/BWT  2   EM (n  5   12) EM  1   BWT/BE (n  5   21)  P   Value
Male, No. (%) 22 (76) 9 (75) 19 (91) .37
Age, y, mean (range) 64 (43-83) 71 (60-84) 69 (47-85) .07
Ex-smoker, No. (%) 17 (59) 11 (92) 12 (57) .09
Pack-y smoked, mean (range) 48 (18-120) 47 (10-153) 55 (10-134) .68
Exacerbation history in previous y 4.0 (0.5) 3.9 (0.9) 5.1 (0.5) .32
BMI, kg/m  2  25.2 (0.9) 28.2 (1.4) 24.7 (0.4) .10
Sputum total cell count   3  10 6   cells/g, 
  geometric mean (95% CI)
3.2 (2.0-5.2) 8.4 (4.3-16.5) 3.6 (1.7-7.7) .18
Sputum neutrophils, % 70 (4) 77 (6) 65 (6) .44
Sputum eosinophil, %, geometric mean (95% CI) 1.6 (0.9-2.8) 0.8 (0.4-1.7) 1.3 (0.6-2.7) .55
Potential pathogenic organism, % 14 25 38 .08
Sputum neutrophil count   3  10 6   cells/g, 
  geometric mean (95% CI)
2.3 (1.3-4.0) 6.3 (2.8-14.1) 1.9 (0.8-4.8) .18
Total bacterial load (16S), geometric mean (95% CI) 1.5  8   (6.6 7 -3.2 8 ) 1.7 8   (3.5 7 -8.1 8 ) 1.5 8   (3.2 7 -6.7 8 ) .99
Colony forming units per mL of sputum, 
  geometric mean (95% CI)
1.4  6   (6.3 5 -3.0 6 ) 1.2 6   (1.5 6 -9.1 6 ) 7.8 5   (3.0 5 -2.0 6 ) .71
FEV  1   % predicted  a  41 (3) 59 (5) 37 (4)   ,  .01
FEV  1 /FVC, a   % 42 (2) 56 (4) 44 (2) .01
Reversibility, % 4.0 (1.9) 3.0 (2.9)   2 0.4  (3.3) .44
RV, % 162 (10) 115 (10) 139 (10) .02
Total lung capacity, % 124 (10) 99 (5) 103 (7) .13
D  lco  , mL CO/min/mm Hg 4.0 (0.3) 5.8 (0.6) 3.6 (0.3)   ,  .01
D  lco   % predicted 46 (4) 73 (7) 32 (4)   , .01
D  lco /V a  , mL CO/min/mm Hg/L 0.8 (0.1) 1.0 (0.1) 1.3 (0.4) .37
D  lco /V a   % predicted 56 (5) 89 (10) 49 (4)   ,  .01
SGRQ total, units 57.9 (3.1) 52.3 (3.5) 56.4 (3.6) .61
CRQ total, units 3.79 (0.21) 4.07 (0.31) 4.11 (0.26) .57
VAS total, mm 163 (13) 143 (25) 126 (18) .24
Data are presented as mean (SEM) unless otherwise indicated. D  lco   5   diffusing capacity of the lung for carbon monoxide; V  a   5   alveolar volume; 
RV  5   residual volume. See Table 1 and 2 legends for expansion of other abbreviations.
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evidence of a lack of correlation between sputum 
neutrophils and EM score in patients with COPD,    15,41   
and outlines the radiologic complement to pheno-
typing COPD. The evidence of eosinophilic airway 
inﬂ  ammation and CT imaging in patients with COPD 
has been conﬂ  icting.    40,42    However,  these  differences 
could be accounted for by differences in study design. 
Interestingly, Miller and colleagues    42    found  close 
correlations between eosinophil degradation prod-
ucts and EM score in a group of well-characterized 
patients with COPD, suggesting that these may con-
tribute to the progression of EM. 
  In this study, we have shown that FEV  1   using 
regression model analysis was not predictive for the 
identiﬁ  cation of EM, BE, or BWT on CT scan. This 
further illustrates the reduced accuracy of FEV  1   in 
identifying the key pathologic processes of COPD. 
On the other hand, CT scan COPD phenotype 
identiﬁ  cation has been associated with key clinical 
outcomes,  including bronchodilator reversibility,    39,43   
effect of airﬂ  ow obstruction,    11     and severity of COPD 
exacerbations.  44     We also concluded that the use of 
conventional lung function testing alone was unable 
to delineate between patients with EM alone and 
those with EM plus phenotypes. 
  Using cluster analysis, an unbiased statistical 
approach investigating airway physiologic pattern 
expression, we identiﬁ  ed three clusters that were 
largely clinically indistinguishable in the expression 
of airway inﬂ  ammation, bacterial load, and quality-
of-life scores. These clusters identiﬁ  ed two emphyse-
matous groups discrete by the degree and severity of 
hyperinﬂ  ation and gas exchange, and a third group that 
was heterogeneous. Although largely useful, physiology 
alone could not clearly and robustly identify the patho-
logic processes seen in COPD. The application of 
CT imaging provided additional clinically important 
information as a noninvasive biomarker in COPD.    20   
  One limitation of this study is that we used qualita-
tive and not quantitative classiﬁ  cation of EM, BE, and 
  Table 5—  Extracted Factors With Eigenvalues   .   1 Using 
Unsupervised Principal Component Analysis for Airway 
Physiologic Parameters   
Correlation Matrix
Factors
12 3
FEV  1 /FVC,  %   2 0.49 0.60 …
FEV  1   % predicted   2 0.35 0.44 0.74
VC, % … … 0.94
FRC, % 0.89   2 0.40 …
RV, % 0.85 … …
TLC, % 0.90 … …
D  lco ,  % … 0.93 …
D  lco /V a ,  % … 0.95 …
FRC  5    functional residual capacity; TLC    5    total lung capacity; 
VC  5   vital capacity. See Table 3 for expansion of other abbreviations.
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BWT. Although this qualitative description of EM, BE, 
and BWT introduces bias into a study such as this 
one, we aimed to reduce this by showing substantial 
agreement between two observers in using this form 
of radiologic description.    36     Future studies that use 
similar unbiased statistical approaches combining mul-
tiple dimensions of airway inﬂ  ammation, physiology, 
and structure determined by quantitative densitom-
etry and geometry are required. The study investigated 
patients who were concurrently enrolled in a longitu-
dinal “biomarkers in COPD exacerbation” study. This 
may have introduced selection bias in the physiologic 
analysis because the indication for CT scan was pri-
marily for clinical purposes, namely malignancy, BE, 
and lung volume reduction surgery. However, as com-
monly found in clinical practice, the group with COPD 
was likely to have measures of lung function with 
imaging in a selected group only; our study thus 
highlights that lung function tools alone do not 
clearly identify important pathologic processes that 
may subsequently alter management. The time inter-
  Table 6—  Demographic and Clinical Characteristics of Physiologic Clusters in COPD   
Characteristic  
Cluster 1 (EM-Predominant, 
Moderate Lung Function 
[n  5   30])
Cluster 2 (Heterogeneous, 
Lung Function Preserved 
[n  5   20])
Cluster 3 (EM-Predominant, 
Severe Lung Function 
[n  5   14])  P   Value
Male, No. (%) 23 (77) 17 (85) 12 (86) .68
Age, y, mean (range) 68 70 64 .23
Pack-y smoked, mean (range) 63 32 44   ,  .01
Exacerbation history in previous y 4.3 (0.5) 3.3 (0.6) 4.6 (0.6) .25
BMI, kg/m  2  24.6 (0.8) 28.8 (1.2) 24.9 (1.3) .01
Sputum total cell count   3  10 6   cells/g, 
  geometric mean (95% CI)
4.2 (3.3-6.8) 4.7 (3.6-8.0) 3.4 (2.1-8.6) .79
Sputum neutrophils, % 68 (5) 68 (5) 73 (6) .77
Sputum eosinophils, %, 
  geometric mean (95% CI)
1.6 (1.2-2.9) 0.8 (0.6-1.4) 2.0 (1.3-4.5) .17
Potential pathogenic organism, % (95% CI) 41 (23-61) 11 (2-34) 20 (5-52) .09
Absolute neutrophil count   3  10 6   cells/g, 
  geometric mean (95% CI)
2.8 (2.0-5.0) 3.0 (2.2-5.8) 2.3 (1.4-6.6) .91
Total bacterial load (16S), 
  geometric mean (95% CI)
2.6  8   (1.6 8 -6.6 8 ) 1.4 8   (7.9 7 -4.2 8 ) 6.8 7   (3.6 7 -2.4 8 ) .30
Colony-forming units, 
  geometric mean (95% CI)
7.2  5   (4.5 5 -1.8 8 ) 1.5 6   (9.4 5 -3.6 6 ) 2.9 6   (1.7 6 -8.2 6 ) .17
FEV  1   % predicted  a  45 (4) 62 (3) 27 (3)   ,  .01
FEV  1 /FVC, a   % 45 (2) 58 (3) 35 (2)   ,  .01
Reversibility, % 4 (2) 5 (3)   2 3  (4) .12
RV, % 143 (3) 88 (6) 194 (11)   ,  .01
TLC, % 110 (4) 85 (5) 124 (4)   ,  .01
D  lco /V a   % predicted 63 (4) 90 (6) 42 (4)   ,  .01
SGRQ total, units 54 (3) 53 (5) 57 (4) .79
CRQ total, units 3.8 (0.2) 4.3 (0.3) 4.3 (0.3) .30
VAS total, units 154 (13) 164 (16) 102 (18) .03
VAS dyspnea, mm 53 (4) 44 (6) 38 (8) .13
VAS cough, mm 41 (5) 45 (6) 25 (8) .12
VAS sputum production, mm 35 (4) 38 (7) 28 (8) .53
VAS sputum purulence, mm 25 (4) 39 (6) 11 (3)   ,  .01
EM, % (95% CI) 80 (62-91) 25 (11-47) 93 (66-100)   ,  .01
BE, % (95% CI) 23 (12-41) 35 (18-57) 21 (7-48) .58
BWT, % (95% CI) 37 (22-55) 5 (0-25) 29 (11-55) .04
Data are presented as mean (SEM) unless otherwise indicated. See Table 1, 2, 3, and 5 legends for expansion of abbreviations.
  a Postbronchodilator.
val between characterization and CT scanning had 
a median of 15 months and may have affected the 
stability of the physiologic phenotype. We found in a 
large cohort of subjects with COPD that parameters of 
spirometry (namely, FEV  1   and FVC) were unchanged 
12 months after characterization, and that measures 
of detailed lung function were also repeatable in this 
cohort. This further conﬁ  rms our ﬁ  nding that the 
use of physiology that is repeatable can identify an 
EM phenotype, whereas imaging is required to iden-
tify BE and BWT in COPD. Whether the presence of 
radiologic BE and BWT in COPD alters the clini-
cal prognosis, management, and therapeutic response 
needs to be examined further in larger clinical stud-
ies with speciﬁ  c phenotypic strategies of trial design. 
 Conclusions 
  In conclusion, COPD is a heterogeneous disease 
currently diagnosed and classiﬁ  ed according to spirom-
etry. The application of radiologic imaging can be a www.chestpubs.org CHEST / 140 / 3 / SEPTEMBER, 2011    641 
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useful tool in further “phenotyping” patients with 
COPD where clinical markers of airway inﬂ  amma-
tion and health status are indistinguishable, and where 
static or dynamic lung function tests provide some, 
but not all, clariﬁ   cation  . 
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